Facebook
X
LinkedIn
Forward| Title | Credit | Series date | Member price |
Non-member price |
|---|---|---|---|---|
|
Pharmacologic Management of Cardiac Dysrhythmias 1.25 NAPNAP Contact Hour of which 1.25 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a recorded presentation for NAPNAP's 20255 National Conference. This presentation will focus on the treatment of common dysrhythmias seen in children, specifically pharmacologic options. We will review both inpatient and outpatient management of various dysrhythmias. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
Keeping Current in Atopic Diseases 1.25 NAPNAP Contact Hour of which 1.25 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a recorded presentation for NAPNAP's 20255 National Conference. The field of Allergy & Immunology continues to expand and incorporate new therapeutics to manage difficult diseases. In 2024, new drugs have been approved that can revolutionize treatment for disease management. Patients will look to their primary care clinicians to be knowledgeable and a resource for these therapeutics. This panel will include three NP experts from food allergy centers at the Children’s Hospital of Philadelphia and University of Texas Southwestern and will discuss biologics, immunotherapy options and non-IgE mediated disease updates for food allergy. NAPNAP’s Asthma and Allergy SIG is pleased to support this session. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
Human Trafficking: Raising Awareness to Identify Victims in the Clinical Setting Providers must register for a free PedsCE account, and be logged in to watch the webinar and receive the certificate. This course was created in collaboration with NAPNAP Partners for Vulnerable Youth. This continuing education activity is offered free for NAPNAP members and nonmembers. |
|
10/06/2020 to 08/29/2027 | $0.00 | $0.00 |
|
Leucovorin in Autism: An Evidence-Based and Clinically Informed Approach 1.25 NAPNAP Contact Hours of which 1.25 contains pharmacology content. This continuing education activity is offered free for NAPNAP Members and non-members. This presentation synthesizes the evidence on folinic acid in autism, with an emphasis on advances since 2018 within the context of foundational work. We will examine the pathophysiology of cerebral folate deficiency (CFD), clarify genetic contributors (e.g., FOLR1 and folate-pathway variants), and review clinical testing with folate receptor-α autoantibodies and related labs. Practical treatment guidance will cover formulation selection, dosing and titration, monitoring, adverse effects, and pharmacy/compounding and cost considerations. Taught by a clinician with extensive real-world experience, the presentation highlights where the evidence is strongest and how to implement it. Learners will finish with a concise, evidence-based framework for evaluating and managing CFD in autism within standard practice. |
|
11/12/2025 to 11/30/2027 | $0.00 | $0.00 |
|
Influenza 2025-2026: Is Your Pediatric Practice Ready? 1.0 NAPNAP Contact Hour of which 0.75 contain pharmacology content. This continuing education activity is offered free for NAPNAP Members and non-members. As we enter influenza season, pediatric-focused APRNs can increase their knowledge and prepare to counsel families and restore confidence in influenza vaccines. This continuing education presentation will teach providers to balance communication of scientific data and vaccine efficacy with acknowledgment of parental concerns and fears, and help families feel empowered to make the best decisions when it comes to flu prevention. |
|
11/14/2025 to 11/30/2026 | $0.00 | $0.00 |
|
JPHC CE: Monitoring Vaccine Safety: United States Vaccine Safety Surveillance Systems 1.0 NAPNAP contact hour of which contain 1.0 pharmacology content. This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Immunization is an effective public health tool to protect children from hospitalization and death from vaccine-preventable diseases. Vaccine safety monitoring is essential to understand risks of vaccination. The Centers for Disease Control and Prevention closely monitors vaccine safety through multiple surveillance systems, including V-safe, the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. This paper briefly discusses each surveillance system and available evidence that healthcare providers can use to respond to common vaccine concerns. As trusted sources of information about vaccines, pediatric nurses and nurse practitioners need to understand how vaccine safety is monitored, where to access reliable resources about vaccines, and when and where to report adverse events noted after vaccination. J Pediatr Health Care (2026) 40, Issue 1, P174-186. |
|
01/01/2026 to 02/28/2027 | $0.00 | $10.00 |
|
JPHC CE: Sexting and Sextortion in Adolescents: Essentials for the PNP 1.0 NAPNAP contact hour. This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Sexting and sextortion are increasingly common concerns among adolescents, presenting significant challenges for pediatric nurse practitioners (PNPs). Sexting, or digital sharing of self-produced nude or otherwise sexual images, is increasingly seen as a normative part of adolescent sexual exploration, but carries substantial risks, particularly when images are shared non-consensually, by minors, or used as a method of bullying or extortion (“sextortion”). PNPs play a critical role in early identification of any nonconsensual texting and by providing education to adolescents so they may explore their sexuality safely, resist peer pressure, and maintain boundaries. J Pediatr Health Care (2026) 40, Issue 1, P162-173. |
|
01/01/2026 to 02/28/2027 | $0.00 | $10.00 |
|
JPHC CE: Gene Therapy: A New Hope in Sickle Cell Disease Treatment 1.0 NAPNAP contact hour of which 1.0 contain pharmacology content. This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Sickle cell disease (SCD) is a lifelong disease requiring expensive treatment for management and limited curative options until the last few years. Gene therapy has emerged as a curative option for SCD, with two approved therapies available to SCD patients aged greater than 12 years. Consideration must be considered regarding the ethics, efficacy, management requirements, education, and counseling needs of patients and their parents. Current and future practices will need to advocate for improved access and affordability of this specialized care and address the unknown and less defined areas of gene therapy pertaining to SCD through research. J Pediatr Health Care. (2025) 39, Issue 1, 122-128. |
|
01/01/2025 to 02/28/2026 | $0.00 | $10.00 |
|
JPHC CE: The Landscape of Substance Use in Youth-2024 1.0 NAPNAP contact hour. This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. An essential role of pediatric providers is to counsel youth and parents on behavioral health issues, including the use of Alcohol or other drugs (AODs). Although substance use by adolescents has decreased, a significant number of adolescents use AODs, causing those with regular use to be at risk of developing behavioral, physical, and mental health consequences that can continue into adulthood. This article was written to help pediatric providers understand the scope and associated effects of AOD use in their adolescent patients and equip them to counsel, identify, and intervene to reduce the harm to their patients who use AODs. J Pediatr Health Care (2025) Issue 6, p1-12. |
|
11/01/2025 to 12/31/2026 | $0.00 | $10.00 |
|
JPHC CE: Approaches to Treating Children With ADHD and Common Comorbidities 1.0 NAPNAP contact hour of which 1.0 contain pharmacology content (Rx), (1.0 is related to psychopharmacology), (0.25 is related to controlled substance). This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Attention Deficit Hyperactivity Disorder (ADHD) is the most common mental health disorder among children and adolescents, with a prevalence rate of 9.8% in children 3 to 17 years of age (Bitsko et al., 2022). The American Academy of Pediatrics (AAP) has published guidelines for treatment of ADHD in children and adolescents ages 4 to 17 years that address diagnosis, treatment and monitoring of ADHD (Wolraich et al., 2019). The AAP guidelines do not address treatment of children with co-morbidities but identify the treatment of ADHD in children with comorbidities as an area for future research. To address this gap, a review of ADHD treatment in children with comorbidities including anxiety, depression, substance use disorder (SUD), epilepsy, tic disorders (TD), oppositional defiant disorder (ODD), learning disabilities (LD), autism spectrum disorder (ASD) and sleep disorders was conducted. J Pediatr Health Care. (2025) 39, 318-325. |
|
03/01/2025 to 04/30/2026 | $0.00 | $10.00 |
|
JPHC CE: The Resurgence of Syphilis: A Critical Public Health Concern 1.25 NAPNAP contact hour of which 0.5 contain pharmacology content (Rx). This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Syphilis, a sexually transmitted infection caused by Treponema pallidum, has become a concerning resurgence in recent years, particularly in the United States. Of significant concern is the steep rise in congenital syphilis cases, which poses grave risks to maternal and neonatal health. This article provides an overview of the epidemiology, risk factors, clinical manifestations, screening methods, and treatment strategies for syphilis, with a specific focus on congenital transmission. Drawing upon current literature and guidelines, the paper underscores the importance of early detection and intervention to prevent adverse outcomes associated with congenital syphilis. Furthermore, the article highlights the challenges in syphilis diagnosis, including the interpretation of serological tests and the management of neurosyphilis. Recommendations for practice, including screening protocols and treatment regimens, are discussed in detail. The conclusion emphasizes the urgent need for collaborative efforts among healthcare providers, public health agencies, and community stakeholders to address the syphilis epidemic effectively. By adhering to evidence-based guidelines and leveraging available resources, clinicians can play a pivotal role in reducing the burden of syphilis and safeguarding the health of vulnerable populations, particularly pregnant women and infants. J Pediatr Health Care. (2025) 39, 479-488. |
|
05/01/2025 to 06/30/2026 | $0.00 | $10.00 |
|
2025 Practice Innovation Posters 0.5 NAPNAP Contact Hours. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $5 for NAPNAP Members. For non-members, this continuing education activity rate is $10. This course is archived practice innovation posters from NAPNAP's 2025 National Conference. |
|
05/08/2025 to 05/31/2027 | $5.00 | $10.00 |
|
Addressing Grief in the Pediatric Primary Care Setting 0.5 NAPNAP Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $5 for NAPNAP Members. For non- members, this continuing education activity rate is $10. This course provides an in-depth exploration of the impact of grief on children and adolescents. PNPs are well-placed to provide grief support to our patients. We will discuss developmental differences in children and teens, discuss strategies to support the grieving youth, recognize signs of complicated grief, and when to refer to specialized providers that can provide additional support. |
|
06/18/2025 to 06/01/2027 | $5.00 | $10.00 |
|
JPHC CE: Preventing HIV in the Adolescent Population with PrEP: The Role of the Nurse Practitioner 1.0 NAPNAP contact hour of which 1.0 contain pharmacology content (Rx). This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Preexposure prophylaxis (PrEP) uptake remains low among adolescents and young adults at high risk due to various barriers, such as decreased access to care, human immunodeficiency virus (HIV) stigma, and misinformation. The barriers to the uptake of PrEP among adolescents and young adults are multifaceted and require comprehensive mitigation strategies. Presented is the epidemiology of HIV, pathophysiology, and complications of HIV in adolescents, history of PrEP research, “How to End the HIV Epidemic in the U.S.” plan, reviewing and eliminating barriers to PrEPcare, PrEP curriculum opportunities for the provider, and the role of the nurse practitioner in reducing new HIV diagnoses in adolescents. J pediatr Health Care. (2025) 39, 503−514. |
|
05/01/2025 to 06/30/2026 | $0.00 | $10.00 |
|
JPHC CE: Diagnosis and Management of Pediatric Allergic Rhinoconjunctivitis in the US 1.0 NAPNAP contact hour of which 0.5 contain pharmacology content (Rx). This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Allergic rhinoconjunctivitis (AR/C) is a common pediatric condition. The physical, emotional, and social burden of AR/C in children highlights the need for accurate diagnosis with optimal treatment. This review provides practical information on the diagnosis and management of pediatric AR/C. Key features of the patient history and physical exam needed to diagnose seasonal and perennial AR/C are covered. Various AR/C treatment options are reviewed such as allergen avoidance, pharmacotherapies, and allergy immunotherapy (both subcutaneous injections and sublingual tablets) as well as their mode of action, side effects, and their role in guideline-recommended therapy. Practical information such as pollen calendars, management algorithms, and treatment product characteristics have also been included in this review. J Pediatr Health Care. (2025) 39, 489-502. |
|
05/01/2025 to 06/30/2026 | $0.00 | $10.00 |